Octapharma Announces Two Hemophilia A Clinical Trials Utilizing Wilate

The following is excerpted from a press release from Octapharma USA. Read the press release in it’s entirety here. 
Octapharma USA has announced that WILATE®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection will be utilized for two important clinical trials for hemophilia A launching in December.
Octapharma USA will fund an investigator-initiated multi-center clinical trial that aims to investigate one of the major challenges facing hemophilia A treatment – the time it takes to decrease inhibitor levels. Jonathan Ducore, M.D., M.P.H. of the University of California Davis School of Medicine and Courtney Thornburg, M.D., M.S., of the Rady Children’s Hospital-San Diego are the principal investigators for the study, entitled “Individualized ITI Based on FVIII Protection by VWF (INITIATE).” The study evaluates a personalized medicine approach to eradicating inhibitors in hemophilia A treatment.
The second study announced by Octapharma will investigate the pharmacokinetics, efficacy, safety, and immunogenicity of WILATE® in previously treated patients with severe hemophilia A. This prospective, international, multi-center Phase 3 study seeks 55 male participants at clinical trial sites in the U.S. and Europe.